Why this Matters
The Plaintiffs allege that the Food and Drug Administration’s (FDA) approval of the abortion drug mifepristone and FDA’s regulations increasing safe access to mifepristone violate the Administrative Procedure Act, the Food, Drug, and Cosmetic Act, the Comstock Act, and are ultra vires. Ensuring that individuals have access to FDA-approved medication abortions enables patients to receive necessary reproductive health care.
Potential Impact
Preventing individuals from accessing effective medication for abortion services will jeopardize their health and safety. Additionally, preventing the FDA from making clinical and scientific determinations will endanger the agency’s ability to ensure individuals have access to safe and effective drugs.